Novartis has established FortiHFy, a global clinical programme, to generate additional data on the effects of the company’s novel heart failure medicine, Entrestro
FortiHFy is the largest clinical programme in heart failure disease across the pharma industry, according to Novartis.
The programme comprises of over 40 active or planned clinical studies designed to generate an array of additional data on symptom reduction, efficacy, quality of life benefits and real world evidence with Entresto and extend understanding of heart failure, according to Novartis.
Vas Narasimhan, global head, drug development and chief medical officer, said: "The FortiHFy programme reinforces our long term commitment to improving heart failure treatment for as many people as possible.
"The outcomes of these trials will increase our understanding of heart failure, the patient population who may benefit from Entresto and could potentially support applications to regulatory authorities".
FortiHFy trials that are already active are posted on clinicaltrials.gov and are currently enrolling patients in more than 50 countries worldwide.
Entresto is approved in 57 countries to date for the treatment of heart failure with reduced ejection fraction (HFrEF), based on data from the PARADIGM-HF study which reported results in 2014.